Core Insights - Shenzhen Borui Pharmaceutical Co., Ltd. announced the successful completion of Phase I clinical trials for its innovative drug BrAD-R13 tablets, aimed at treating Alzheimer's disease (AD), marking a significant milestone in drug development for millions of patients globally [1] Company Developments - The Phase I trial validated the safety and pharmacokinetic properties of BrAD-R13 in human subjects, providing new hope for Alzheimer's patients [1] - Longgang District's Science and Technology Innovation Bureau reported that Kewi Pharmaceutical (Shenzhen) New Drug Research Center has made significant progress in developing innovative drugs, potentially offering new treatment strategies for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus [1]